Definitive Contract 75D30121C10167
Award Date 1/1/21
Potential Completion Date 12/31/30
Potential Value $14M
Federal Agency
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
22
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Weill Medical College of Cornell University received a definitive cost-no-fee contract from the Centers for Disease Control and Prevention (CDC) to provide tuberculosis clinical trials and consortium services, with a ceiling value of $5.9M and performance through December 31, 2030. The contract, awarded January 1, 2021, supports the CDC's Tuberculosis Trials Consortium by enabling participation in clinical research studies, including study startup procedures, concurrent management of multiple...
- The Centers for Disease Control and Prevention (CDC) awarded a definitive cost-no-fee contract valued at $3.78M to Denver Health and Hospital Authority for tuberculosis trials and consortium services. The contract, effective January 1, 2021, and extending through December 31, 2030, supports clinical research activities under the CDC's broader tuberculosis prevention and treatment initiatives. Denver Health will serve as a participating site in the Tuberculosis Trials Consortium, conducting...
- The Centers for Disease Control and Prevention (CDC) Pittsburgh division awarded a $10.67 million cost-reimbursable contract to King County's Public Health-Seattle & King County division on January 1, 2021, with a completion date of December 31, 2030. This definitive contract, awarded competitively with no set-aside designation, supports tuberculosis clinical trials and consortium services. The primary deliverables include participation in clinical research studies, adherence to study...
- The Medical University of South Carolina (MUSC) was awarded a cost-reimbursable, definitive contract by the Centers for Disease Control and Prevention (CDC) Pittsburgh office on January 1, 2021, to support clinical research services for the Tuberculosis Trials and Consortium. The contract has a ceiling value of $9.86 million and extends through December 31, 2030, with performance conducted in South Africa. This award emerged from a pre-solicitation notice issued in February 2020 seeking clinical...
- The Centers for Disease Control and Prevention (CDC) awarded a $4,455,976 cost-no-fee definitive contract to The Regents of the University of California, San Francisco (UCSF) to develop, implement, and evaluate interventions to improve latent tuberculosis infection (LTBI) identification and treatment among high-risk non-U.S.-born populations in primary care settings. This contract, known as Tuberculosis Epidemiologic Studies Consortium III (TBESC3), has a period of performance from September 29,...
- Duke University, as prime contractor, was awarded a $4.3 million delivery order against the Tuberculosis Epidemiology Studies Consortium master IDIQ by the Centers for Disease Control and Prevention. The contract calls for enrollment, preventive treatment, data collection and analysis of latent tuberculosis infection patients. Major subcontractors include Atrium Health and Vanderbilt University, which will assist with performance of the clinical work. The goal of the project appears to be...
- Case Western Reserve University (CWRU) was awarded a definitive contract by the Centers for Disease Control and Prevention (CDC) Pittsburgh office to provide tuberculosis trials and consortium services in Uganda. The contract, valued at approximately $15.7 million with a cost-no-fee pricing structure, runs through December 31, 2030, and was awarded on January 1, 2021, following a pre-solicitation notice posted in February 2020. Under this contract, CWRU will support clinical research...
- The Centers for Disease Control and Prevention (CDC) awarded a $4,679,587.20 Definitive Contract to the Denver Health and Hospital Authority (Denver Health) to develop, implement, and evaluate intervention studies to improve identification of latent tuberculosis infection (LTBI) and treatment-to-cure for high-risk non-U.S.-born populations in primary care settings. This contract, which does not have a set-aside designation, has a period of performance from September 29, 2021 through March 28,...
- This is a $2,054,175.16 federal contract awarded by the Centers for Disease Control and Prevention (CDC) to PPD Development LP, a global contract research organization (CRO), for monitoring services in support of the Tuberculosis Trials Consortium (TBTC). The contract is a 5-year definitive contract with a time and materials pricing type. It will involve on-site monitoring, quality assurance, investigational product management, and reporting for TBTC clinical trials of new drugs, diagnostics,...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $1,434,867.00 definitive cost-no-fee contract to The Johns Hopkins University to support the Tuberculosis Trials Consortium (TBTC). This contract, which does not have a set-aside designation, was awarded on September 18, 2019 and has a completion date of March 17, 2021. The Johns Hopkins University, a private non-profit research university, will provide clinical trial and data coordination services...